Immunopeptide PEPITEM Can Reduce Chronic Inflammatory Reactions in Old Mice
Researchers have discovered an immunomodulatory peptide, PEPITEM, that effectively reduces the migration of adaptive immune cells triggered by inflammatory signals. This breakthrough aims to address the role of excessive immune cell migration in chronic inflammation associated with aging, which is often caused by age-related changes in immune cell behavior. By delivering PEPITEM, researchers hope to restore a more youthful regulation of immune cell behavior.
Recent studies indicate that aging significantly affects the dynamics of leukocyte trafficking during inflammation, leading to a compromised immune response. One notable observation is the increased migration of neutrophils and monocytes to the peritoneal cavity in aged mice, driven by pro-inflammatory mediators and enhanced vascular permeability. However, the impact on lymphocyte trafficking in the aging process remains unclear.
To further investigate these changes, researchers conducted a study utilizing a novel immunopeptide, PEPITEM, in a zymosan-induced peritonitis model in young and aged mice. This model, although simplified, offers valuable insights into early inflammatory events and immune cell recruitment. By targeting the leukocyte trafficking pathway with PEPITEM, researchers observed a restoration of functionality in aged mice, highlighting the potential of PEPITEM supplementation as a geroprotective strategy to enhance immune functions in older individuals.
